Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2 (aka “COVID-19”) vaccine candidate. Ufovax holds an exclusive global license to the Scripps Intellectual P

Click to view original post

Advertise With Us